Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Saved in:
| Title: | Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). |
|---|---|
| Authors: | Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, 390 Victoria Street, Sydney, NSW 2010, Australia.; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., John N; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Pathmanandavel S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Counter W; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Ayers M; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Sharma S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Agrawal S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Poole A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Hovey E; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia., Pranavan G; Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia., Gedye C; Calvary Mater Hospital, Newcastle, NSW, Australia., Mallesara G; Calvary Mater Hospital, Newcastle, NSW, Australia., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia., Lee A; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Hickey A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Eu P; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia., Joshua AM; The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Crumbaker M; Garvan Institute of Medical Research, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.; The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 01; Vol. 15, pp. 17588359231156392. Date of Electronic Publication: 2023 Mar 01 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
